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Colorectal cancer 
Colorectal cancer is one of the most common causes of cancer in the western 
world. Approximately 50% of patients develop metastases with only a minority 
being eligible for a metastasectomy with curative intent. The majority can only 
be considered for palliative systemic treatment. Over the past decades, the 
options for systemic treatment have improved considerably, from 5-FU as the 
only available drug to treatment with other cytotoxic drugs such as oxaliplatin 
and irinotecan, and targeted agents such as antibodies to the vascular 
endothelial growth factor (VEGF) and the epidermal growth factor receptor 
(EGFR). These new therapies as well as the more frequent use of surgical 
resections of metastases have improved median overall survival from 
approximately 10-11 months to currently about 30 months(1-3).  
 
DCCG 
The Dutch Colorectal Cancer Group (DCCG) is a national multidisciplinary 
clinical research group in The Netherlands that aims to stimulate clinical 
research and to improve the quality of diagnosis and treatment of patients with 
colorectal cancer, with practice changing trials. In January 2003 the DCCG 
initiated the CAIRO study, a randomized phase 3 study in patients with 
metastatic colorectal cancer (mCRC). Since then 2133 patients with mCRC were 
treated in three consecutive phase III trials(4-6), and the 4th and 5th study are 
currently open for accrual(7, 8). CAIRO is a acronym for the drugs used in the 
first study: CApecitabine, IRinotecan and Oxaliplatin. After the success of this 
study it was decided to maintain this acronym for subsequent studies. The 
results of the first 3 trials have been incorporated in national and international 
guidelines.  
 
The final stage of the development of new drugs or treatment strategies is the 
conduct of phase III trials in which an investigational therapy or strategy is 
compared with the standard of care. The primary endpoint of these studies may 
vary and depends on the context in which the new therapy is used. The final 
purpose is to improve the outcome of patients either by a benefit in survival or 
improved quality of life due to less toxicity of equally effective therapies, as 
quality of life is being increasingly recognized as an important outcome 
parameter. Obviously, it is essential that this research should be of high quality 
and meets (inter)national standards of conduct.  
  
The design and conduct of phase III clinical trials requires great effort and 
resources, since patients trust their (quality) of life to the investigations, while 
the required number of patients as well as the number of participating centres 
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is large. These efforts are therefore only justified if the results are expected 
to be, reliable and clinically relevant. We are also obliged to the participating 
patients only to include patients in good studies, as they are willing to take the 
risk of a new treatment which has not be proved to be effective and could have 
unknown side effects. Therefore the design, conduct, analysis and reporting of 
clinical trials should be of the highest quality. Although there is not a clear 
definition or international guideline of what we consider high quality research, 
several issues can be addressed on this topic. This will be discussed in the next 
paragraphs.  
 
Protocol design 
A clinical trial starts with the design of a protocol. In the Netherlands, a 
standard protocol has been developed and made available by the Central 
committee on Research Involving Human subjects (CCMO) which contains all 
relevant topics that should be addressed. Among others these concern an 
introduction in which the rationale for the study and the objective(s) are 
explained; definition of the research population with data on the planned 
number of patients and feasibility; a statistical paragraph with justification of 
the design and eligibility criteria for reasons of patients’ safety and limitation 
of selection bias.  
In the methods section all study procedures must be described clearly and 
specifically, i.e. treatment, dose reductions, evaluations, diagnostic tests, and 
follow-up. This is to minimise procedure variation between individual 
investigators.  
 
 All clinical trials have to be reviewed by an accredited medical ethical 
committee(MEC) which has to address the following issues (section 3 
WMO): 
 The scientific research contributes to new insights in the field of 
medicine. 
 There are no simpler or less intrusive alternatives (for example; 
preferably no minors or incapacitated subjects). 
 The importance of the research is in proportion to the objections 
(burden) and the risks to the research subjects. 
 The study meets the scientific requirements for research. 
 The research is led or carried out by professionals. 
 Any financial compensation for the research subject does not form part 
of the reason for participating in the research. 
 The protocol states the extent of the benefits for the subjects as a 
result of participation in the study (in the case of group therapy: the 
benefits for the group to which the subject is assigned). 
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One of the issues concerns the risks the research subject is exposed to. During 
the study this is monitored by the reporting of Serious Adverse Events (SAEs). A 
SAE is any untoward medical occurrence that at any dose results in death, is 
life-threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect (ICH-GCP article 1.50). Besides the study team 
SAEs are also monitored by the MEC and the independent data monitoring 
committee (IDMC). 
Accrual 
After a protocol has been approved by the ethics committee, the study accrual 
can start. It is important to realize that in The Netherlands only 3.5 % of the 
total number of new cancer patients are enrolled in CKTO and EORTC trials, 
which are the majority of investigator-initiated trials. One of the goals of the 
Dutch Cancer Foundation is to increase the number of participants in clinical 
trials (KWF beleidsvisie 2006-2011).  
Obviously, a fast accrual facilitates that trial results become available more 
rapidly, which is in the interest of patients and general healthcare. A slow 
accrual may endanger the relevance of the primary objective of the trial, the 
quality of the trial since practice may change over time and more over, trials 
that are discontinued early due to poor accrual are a waste of resources. 
 
Quality assurance 
When the protocol meets sufficient standards in terms of quality and feasibility, 
the next step is to ascertain the strict adherence to the protocol. Deviations 
from the protocol may impact on the outcome of the trial obscuring the true 
effects of the treatment arms. Adherence to the protocol in trials with 
anticancer drugs consists of specific aspects, such as, the correct preparation 
of the drugs, administration and dose adjustments in case of toxicity, and the 
assessment of outcome according to scheduled and prescribed methods.  
 
Research on the quality of cancer clinical trials has been started by the EORTC 
quality control programmes in radiotherapy studies in the 1980s followed by 3 
studies which assessed the quality of chemotherapy(9-12). On-site visits were 
performed to investigate the structure and process parameters of the quality 
of chemotherapy, protocol adherence and data quality control. Between 
institutions large differences were observed in available information in the 
hospital files, for instance on chemotherapy dosing, date of administration and 
toxicity registration.  
 
The results of the EORTC studies on quality control have resulted in the 
introduction of the systemic therapy checklist. This checklist contained 
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variables related to eligibility, drug doses and administration, biochemical and 
haematological parameters, variables related to toxicity of treatment and 
response parameters. The use of this checklist improved the problem of missing 
data, from 68% correct data before the introduction to 86 % in the hospitals 
that did not use it, and 98% in the hospitals which did use it. This difference 
was explained by the decrease in missing data from 28% to 11% in the hospitals 
which did not use to 0.6% in the hospitals which did use the checklist(10).  
Research on the quality of systemic treatment in daily practice mainly focuses 
on deviations from clinical guidelines. Registration of actual administered 
chemotherapy and the resulting toxicity were suboptimal according to some 
assessments(13, 14). Suboptimal dosing and timing of systemic therapy is often 
due to avoidable reasons. Reasons for variation should therefore be investigated 
more thoroughly. Some advocate that better protocols in daily practice would 
lead to improvement in quality of care in daily practice (15). Because treatment 
in a clinical trial is well described in the protocol it might therefore result in 
better quality of care for cancer patients compared to treatment in daily 
practice. Many studies have tried to compare outcome between trial-
participants and non-trial participants, but few data are available concerning a 
difference in quality of care. 
 
Publication 
For the publication of clinical trials the Consolidated Standards of Reporting 
Trials (CONSORT) group has developed a checklist and a flow diagram to 
improve reporting of RCTs. A study on the quality of reporting trials in scientific 
journals, showed that many items remained underreported in oncological 
studies(16).  
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As there are no clear guidelines for assessing the quality of clinical trials that 
include the previously mentioned items, we investigated quality of a number of 
aspects in the CAIRO studies.  
During the first CAIRO study we observed many SAEs that clearly required 
further follow-up. This resulted in an on-site monitoring of all fatal SAEs. The 
results of this quality control are described in chapter 2.  
With more than 2000 included patients in the currently completed CAIRO 
studies, with 60%-to 80% of Dutch hospitals participating, this allowed us to 
study the quality of colorectal cancer clinical trials in The Netherlands. Because 
treatment in the first CAIRO trial was similar to treatment in daily practice we 
were able to compare the outcome of patients treated in this trial with those 
treated outside the trial in daily practice. This is described in chapter 3. 
We observed large differences in WHO Performance Score (PS) reporting and 
QoL scores. As an example, a physician scored the WHO PS of a patient as 0, 
while the patient reported to be unable to walk even a short distance. In 
chapter 4 we compare the prognostic value of patient reported QoL and 
physician reported WHO PS.  
Finally, it is often stated that protocol adherence is lower in centres with poor 
accrual (i.e. less than 5 patients) compared to centres with high accrual, and 
that low accruing centres may therefore harm the quality of the trial. In The 
Netherlands hospitals can be divided according to size and infrastructure in 
regional hospitals, STZ hospitals and academic hospitals. We investigated 
whether there is a difference in quality of trial performance between these 
type of hospitals. In chapter 5 we address this issue and try to find factors 
which can explain differences between hospitals.  
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Background 
Early and correct assessment of treatment-related mortality is highly important 
in clinical cancer trials. However, no data are available on the quality of safety 
monitoring.  
 
Patients and methods:  
An on-site review was performed by the study coordinators of the individual 
charts of all patients participating in the CAIRO study (1) who had died within 
30 days of the last administration of study drugs when death was accompanied 
by any other event than disease progression. The relationship between 
treatment and death was categorized as unrelated, remote, possible, or 
probable, and submitted to an independent data monitoring committee (IDMC). 
These results were then compared with the initial assessment of the local 
investigator. 
 
Results: 
Forty out of 820 patients qualified for review. The relationship between cause 
of death and study drugs was changed in 26 patients (65%). A major protocol 
violation (MPV) was identified in 12 out of 14 patients with a probable 
relationship between cause of death and study treatment.  
 
Conclusions:  
There was little agreement between the relation as assessed by the local 
investigator compared to the IDMC. A quality control improves the assessment 
of safety results and the observed MPVs underscore the importance of educating 
medical staff and patients.  
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An important aspect of clinical trials in cancer patients is an early and reliable 
assessment of the relationship between adverse events and treatment. For a 
timely update of this crucial information, serious adverse events (SAE) have to 
be reported according to the International Conference on Harmonisation Good 
Clinical Practice (ICH-GCP) guidelines. As defined by ICH-GCP, a SAE is any 
untoward medical occurrence that at any dose results in death, is life-
threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect (ICH-GCP article 1.50). Most study protocols 
define a period during which SAE have to be reported, and usually this is from 
the signing of the informed consent form until 30 days after the last 
administration of study drug(s). This implies that in clinical trials all 
hospitalizations and deaths occurring within 30 days of last study drug 
administration have to be reported within 24 hours. The SAE reports are 
centrally collected, assessed by the principal investigator(s) (PI) and/or study 
coordinators, and finally submitted to an independent data monitoring 
committee (IDMC).  
The IDMC consists of independent experts to assess intervals the progress of a 
clinical trial, the safety data, and the critical efficacy endpoints, and to 
recommend to the sponsor whether to continue, modify, or stop a trial (ICH-
GCP article 1.25). Within this system the early safety monitoring of clinical 
trials by the PI and IDMC largely depends on the early and reliable assessment 
of SAE reports.  
Although SAE reports are the most important way to monitor the early safety 
and to assess the treatment-related mortality, there is no information available 
about the quality of SAE reporting by the local investigators. We performed a 
quality control on the reporting of SAEs in a large prospective randomised phase 
III trial. 
 
 
 In the CAIRO study of the Dutch Colorectal Cancer Group (DCCG) (1;2) 
registered with ClinicalTrials.gov with the number NCT00312000, 820 patients 
with advanced colorectal cancer (ACC) from 74 Dutch hospitals were 
randomized between 1st line capecitabine, 2nd line irinotecan, and 3rd line 
capecitabine + oxaliplatin (sequential treatment arm) versus 1st line 
capecitabine + irinotecan, and 2nd line capecitabine + oxaliplatin (combination 
treatment arm). Registration of patients was performed by a telephone call or 
fax of the local investigator with the central datamanagement office, which 
included a confirmation of all eligibility criteria. A protocol summary and 
checklist which summarized the eligibility criteria, treatment and evaluation 
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schedule and recommended dose modifications for the most frequently 
expected toxicities was made available to all investigators for inclusion in to 
the file of each participating patient. Furthermore, prior to the initiation of the 
study three regional investigators meetings were organised to inform 
investigators and other research staff about the protocol. The protocol 
contained specific instructions for eligibility both for study entry as well as for 
the initiation of subsequent treatments. As a prospective part of the protocol, 
patients who had died within 30 days of the last administration of study drugs 
and whose death was accompanied by any other event than disease progression, 
irrespective of the causality reported for this event by the local investigator, 
were selected for this analysis. The study coordinators (MK, CJAP) performed 
an on-site review of the individual charts of these selected patients, and they 
assessed the relationship between treatment and death based on all available 
documentation. The relationship of the event to study treatment was 
categorized as either unrelated, remote, possible or probable, as was also 
previously done by the local investigator on the SAE form. The results of the 
assessment by the study coordinators as well as the original SAE reports were 
submitted to the IDMC, who made the final assessment of causality.  
 
Study population 
Of the 820 patients enrolled in the study a total of 746 SAE’s were reported in 
443 patients. These SAE reports included 630 hospitalizations, 112 deaths 
occurring within 30 days of last administration of study drugs and 4 other 
reasons. Of these 112 deaths, 9 were reported ≤ 24 hours, 42 ≤ 2 weeks, and 70 
> 2 weeks after the date of the event, with a median time of reporting of 34 
days (range 0 – 1261). In 72 out of these 112 cases, disease progression was the 
obvious single reported cause of death. The remaining 40 patients were eligible 
for on-site review. The characteristics of these 40 patients did not differ from 
the overall study patient population except for age (median 68 years (range 52-
79) vs 63 (27-84) years respectively, p<0.01). 
 
Review results 
Of the 40 patients whose charts were reviewed, the local investigators assessed 
the relationship between their death and the study medication as unrelated in 
14, remote in 6, possible in 9 and probable in 11 patients. The study 
coordinators assessed the deaths as unrelated in 2, remote in 10, possible in 14 
and probable in 14 (Table 1). The assessment by the study coordinators was 
confirmed by the IDMC in all cases. Compared to the assessment of the local 
investigators as documented on the original SAE reports, the relationship 
between cause of death and study drugs was changed by the review in 26 
patients (65%). In 20 patients (50%) the study coordinators increased the level 
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of causality, with in three patients the causality even being changed from 
unrelated to probable. 
 
 
 IDMC  
 Unrelated Remote Possible Probable Total 
Lo
ca
l i
n
ve
st
ig
at
o
r Unrelated 2 4 5 3 14 
Remote 0 2 4 0 6 
Possible 0 2 3 4 9 
Probable 0 2 2 7 11 
Total 2 10 14 14 40 
Table 1 Causality assessed by local versus the IDMC 
 
Protocol violations 
In the 14 patients whose death was established after review as probably related 
to study treatment, the causes of death were neutropenic sepsis (n=8), 
neutropenic fever (n=2) and dehydration due to diarrhoea (n=4) (Table 2). In 12 
of these 14 patients one or more major protocol violations (MPV) were 
identified. These concerned the administration of chemotherapy despite an 
abnormal renal function (n=1), the administration of irinotecan despite 
elevated serum bilirubin concentration (n=2), continuation of capecitabine 
therapy despite previous or ongoing severe diarrhoea (n=7), and continuation 
of study drugs despite a decreased WHO performance status of ≥ 3 (n=4). In five 
of these 12 patients the MPVs had already been identified by the regular data 
management, and in seven they were identified during the review. In addition 
to these MPVs, four patients were considered ineligible for study participation 
which was not detected after standard data processing. The reasons for 
ineligibility were prior systemic treatment for advanced colorectal cancer 
(n=2), WHO PS 3 and partial bowel obstruction (n=1), and abnormal renal 
function at baseline plus severe leucopenia during prior adjuvant chemotherapy 
(n=1). 
 
  
Chapter 2 
 
22  
Nr Arm Line Cycle Cause of death Protocol violation 
1 A 1 1 Neutropenic fever Not eligible: abnormal renal function 
plus severe leucopenia during prior 
adjuvant chemotherapy 
2 A 1 2 Neutropenic 
sepsis, 
dehydration due 
to diarrhoea and 
vomiting 
Continuation of capecitabine despite of 
diarrhoea grade 2 
3 A 1 3 Diarrhoea Not eligible: prior chemotherapy for 
advanced disease 
Continuation of capecitabine despite of 
diarrhoea 
4 A 1 4 Diarrhoea Continuation of capecitabine despite of 
PS WHO grade ≥3 and diarrhoea grade 3 
5 A 1 4 Neutropenic sepsis No dose reduction despite of PS WHO 
grade ≥3 and grade 3 nausea, vomiting 
and diarrhoea 
6 A 1 4 Sepsis and 
diarrhoea 
Continuation despite of recurrent grade 
3 diarrhoea  
7 A 2 1 Neutropenic sepsis Elevated serum bilirubin at start of 
irinotecan 
8 A 2 1 Neutropenic sepsis Elevated serum bilirubin at start of 
irinotecan 
9 A 2 2 Neutropenic fever None 
10 A 2 31 Neutropenic 
sepsis, diarrhoea  
No dose reduction of capecitabine 
despite of recurrent grade 3 diarrhoea 
11 B 1 1 Neutropenic sepsis None 
12 B 1 1 Neutropenic sepsis Not eligible: WHO PS 3 and partial 
bowel obstruction 
Chemotherapy given despite of WHO PS 
grade ≥3 
13 B 1 1 Neutropenia, 
diarrhoea 
Continuation of capecitabine despite of 
diarrhoea grade 3 
14 B 1 2 Neutropenic 
sepsis, 
dehydration due 
to diarrhoea and 
vomiting 
Continuation of capecitabine/irinotecan 
despite of PS WHO grade ≥3 and 
diarrhoea grade 2 
Table 2 Treatment-related deaths A= sequential chemotherapy, B=Combination 
chemotherapy, PS = performance status 
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To our knowledge this is the first randomised phase III trial in which the quality 
of the SAE reporting was prospectively assessed. For our review 72 of the 112 
SAEs reporting a death occurring within 30 days of the last administration of 
study drugs were excluded because the cause of death was disease progression 
and no other concomitant medical events were reported. Although we did make 
an effort to obtain additional information to confirm this, we acknowledge that 
this may have introduced a selection bias by which we underestimated the 
number of treatment-related deaths. However, the objective of our review was 
not a meticulous quantitative analysis, but a study to assess the quality of SAE 
reporting. 
We recorded a disagreement between the assessment of the local investigators 
and the IDMC on the relationship between the study drugs and death in 65% of 
the patients whose charts were reviewed. Local investigators frequently 
underestimated the relation between the administration of study drugs and 
death. The CAIRO study tested the optimal use of well established cytotoxics 
(capecitabine, irinotecan, and oxaliplatin), and all participating investigators 
had previous experience with the use of these drugs. However, insufficient 
knowledge about the safety profiles and management of toxicities cannot be 
excluded as a cause for the observed underestimation. Another possibility is 
that the short reporting period of 24 hours after the occurrence of the SAE may 
not always allow a full and comprehensive assessment of the SAE. We assume 
this underestimation is not limited to SAEs reporting death, but applicable to 
the reporting of SAEs in general. However, this was not investigated. 
Of concern is the fact that a MPV was involved in 12 out of the 14 treatment-
related deaths. The most frequently occurring MPV was the continuation of 
capecitabine despite the presence of diarrhoea. The cause of death of two 
ineligible patients in this review was probably related to study treatment 
(patient 1 and 12 in table 2). In both patients, the reason of ineligibility likely 
played a role in the observed toxicity leading to death. Another two patients 
were ineligible for second-line treatment with irinotecan because of an 
elevated serum bilirubin, and these patients subsequently died of febrile 
neutropenia. This underscores the importance of educating investigators and 
patients in order to prevent unnecessary severe toxicity and of checking all 
relevant data prior to randomization and initiation of treatment cycles. As 
described in the methods, a protocol checklist containing the most relevant 
information on this subject were distributed to all investigators, but we have 
no information as to its use. Meetings were also organized to inform the 
investigators about the protocol. This is more than the average trial, therefore 
we believe the results do not reflect shortcomings in the study organization but 
a general problem in clinical trials. 
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The results of similar reviews have been published, however these were only 
performed in retrospect upon the occurrence of unexpected severe toxicities. 
Examples in metastatic colorectal cancer studies are EORTC study 40015(3) and 
Intergroup study N9741(4) . EORTC study 40015 (3) was closed after 8 deaths 
unrelated to disease progression had occurred. The individual hospital files 
were inspected and discussed with the physician to determine whether the 
observed deaths were related to or exacerbated by the study treatment. Four 
deaths were considered as related, three as exacerbated, and one as unrelated 
to study treatment. In the Intergroup study N9741(4), a panel of 5 independent 
medical oncologists reviewed the causes of the observed early deaths. Of the 
23 observed deaths, 16 were assessed as treatment-related after central 
independent review. Both reports did not present information on any initial 
discrepancy between the assessments of local investigators and study 
coordinators or independent panel, or on the involvement of any MPV that could 
have attributed to treatment-related deaths. In this respect our results are 
unique, at least to our knowledge. We believe that such information provides 
relevant data, which contribute to an accurate interpretation of study results. 
 
In conclusion, a quality control by on-site review of hospital charts of patients 
experiencing SAEs may improve the quality of the assessment of treatment-
related mortality. This process revealed relevant and new information, such as 
MPVs and patient ineligibilities. This implies that the assessment by the local 
investigator may not reflect the true relationship between a SAE and the study 
medication, and that routine datamanagement may not reveal all relevant 
information. Our data should make investigators and datamanagers aware of 
these pitfalls. The implementation of novel information and communication 
technologies may add to prevent protocol violations as described. 
The implementation of planned reviews as described here as a routine part of 
clinical studies should lead to a better quality of reported data. The review of 
treatment-related mortality is being continued in subsequent CAIRO studies (5), 
and a quality control program has been initiated in which other aspects such as 
protocol adherence are investigated. 
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To the Editor: Dr Ranpura and colleagues performed a meta-analysis on 
treatment-related mortality with bevacizumab in cancer patients.1 The authors 
referred to results of our research that showed a higher overall risk of FAEs in 
cancer patients due to serious toxic effects of chemotherapy.2 We monitored 
FAEs in a study of 820 patients with metastatic colorectal cancer.3 One of our 
main findings, after reviewing individual records of patients experiencing FAEs, 
was a difference in the assessment of the relationship between FAEs and 
treatment between treating physicians and an independent data monitoring 
committee in 65% of patients. Furthermore, we found that major protocol 
violations were involved in the majority of FAEs, which implies that these FAEs 
could have been prevented by more adequate patient care. Therefore, we ask 
the authors whether such monitoring was performed on the FAEs in the studies 
included in their meta-analysis. This would allow a better assessment of the 
possible relationship of FAEs with bevacizumab treatment and would provide 
insights into whether certain FAEs could have been prevented by better 
adherence to treatment guidelines. 
We also question the inclusion in the meta-analysis of studies performed in 
patients with pancreatic and prostate cancer, for which bevacizumab is not 
approved. Of all 6 tumour types that the authors included in their analysis, the 
relative risk of FAEs in these 2 tumour types ranked first and third, respectively, 
and therefore the results in pancreatic and prostate cancer had a relatively 
large effect on the overall result. A tumour-specific interaction between 
bevacizumab and tumour type in terms of toxicity cannot be excluded, as is 
suggested in the case of non–small cell lung cancer with squamous cell 
histology, and bevacizumab-related toxicity may thus have contributed to the 
negative outcome of studies in pancreatic and prostate cancer. Therefore, we 
would consider it more relevant for daily practice if only data from approved 
indications would have been used. 
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Introduction 
The external validity of trial results is a matter of debate, and no strong 
evidence is available to support whether a trial may have a positive or a 
negative effect on the outcome of patients. 
 
Methods  
We compared the results of stage IV colorectal cancer patients treated within 
a large Dutch phase III trial (CAIRO), in which standard chemotherapy and 
standard safety eligibility criteria were used, to patients treated outside the 
trial during the trial accrual period in a representative selection of 29 Dutch 
hospitals. Non-trial patients were identified by the Netherlands Cancer Registry 
(NCR), and were checked for the trial eligibility criteria.   
 
Results  
The NCR registered 1946 stage IV colorectal cancer patients who received 
chemotherapy, of whom 394 patients were included in the CAIRO trial and 30 
patients in other trials. Thus, the CAIRO trial participation rate was 20%. In the 
29 hospitals, 162 patients received chemotherapy in the trial and 396 patients 
received chemotherapy outside the trial. Of the non-trial patients, 224 patients 
fulfilled the trial eligibility criteria. The overall survival of eligible non-trial 
patients was comparable to trial patients (HR 1.03, p=0.70). However, non-
eligible non-trial patients had a significantly worse outcome (HR 1.70, p<0.01).  
 
Conclusion  
These data provide evidence in a common tumour type that trial results have 
external validity, provided that standard eligibility criteria are being observed. 
Our finding of a worse outcome for patients not fulfilling these criteria strongly 
argues against the use of cancer treatments in other patient categories than 
included in the original trials in which these treatments were investigated.  
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Clinical trials are an essential tool for the evaluation of novel medical drugs 
and technologies, and the results of these trials provide the strongest backbone 
of evidence-based medicine. Clinicians often assume that trial participation is 
beneficial for the individual patient, mainly because of the increased attention 
given to trial patients as compared to patients treated in daily practice. 
However, earlier reviews [1-4] have not provided strong evidence that trial 
participation improves outcome, although a trend towards a positive effect was 
noted. These reviews identified differences in interventions as well as patient 
characteristics in- and outside trials as possible confounders. In a more recent 
systematic review, which was not restricted to cancer trials, no evidence was 
found for either a beneficial or a harmful effect of trial participation [5]. 
We have conducted a national multicentre investigator-initiated prospective 
randomized phase III trial in metastatic colorectal cancer patients on the 
sequential versus the combined use of standard cytotoxic drugs: capecitabine, 
oxaliplatin and irinotecan [6,7]. The study medication of this trial concerned 
standard drugs and regimens, which therefore provided the opportunity to 
compare the outcome of trial patients with patients who were treated with 
chemotherapy outside the trial during the trial accrual period. This analysis also 
allowed to assess the trial participation rate. We here present the results of 
this analysis.  
 
 
Patients participating in the trial 
Between January 2003 and December 2004, 820 metastatic colorectal cancer 
patients were included in the investigator-initiated phase III randomized CAIRO 
trial (ClinicalTrials.gov NCT00312000) of the Dutch Colorectal Cancer Group 
(DCCG)[6,7]. Of these, 396 patients presented with stage IV disease (i.e. 
synchronous metastases), of whom 2 patients were later found ineligible and 
were therefore excluded from the survival analysis. CAIRO is the only trial to 
date in which the sequential versus the combined use of all 3 cytotoxic drugs 
with efficacy in colorectal cancer has been prospectively investigated. Patients 
were randomized between first-line capecitabine, second-line irinotecan, and 
third-line capecitabine + oxaliplatin (sequential treatment arm) and first line 
capecitabine + irinotecan and second-line capecitabine + oxaliplatin 
(combination treatment arm). All cytotoxic drugs were administered at their 
recommended doses and schedules, and treatment was required to start within 
one week of randomisation. The main eligibility criteria included histologically 
proven colorectal cancer in an advanced stage not amenable to curative 
surgery, measurable or assessable disease parameters, and no previous systemic 
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treatment for advanced disease. Previous adjuvant chemotherapy was allowed 
provided that the last administration was given at least 6 months before 
randomisation. Eligible patients were required to have a WHO performance 
score of 0-2 and adequate hepatic, bone marrow and renal functions. Exclusion 
criteria included serious concomitant disease preventing the safe 
administration of chemotherapy or likely to interfere with the study 
assessments; other malignancies in the past 5 years with the exception of 
adequately treated carcinoma in situ of the cervix and squamous or basal cell 
carcinoma of the skin; pregnancy or lactation; patients with reproductive 
potential not implementing adequate contraceptive measures; central nervous 
system metastases; serious active infections; inflammatory bowel disease or 
other diseases associated with chronic diarrhoea; previous extensive irradiation 
of the pelvis or abdomen; concomitant administration of any other 
experimental drug; concurrent treatment with any other anti-cancer therapy. 
A total of 79 of the approximately 100 Dutch hospitals participated in this study.  
 
Patients not participating in the trial 
Non-trial patients were identified by using data from the Netherlands Cancer 
Registry (NCR), which registers all cancer patients at primary diagnosis. This 
implies that metastatic patients are only registered when they present with 
synchronous metastases, i.e. stage IV. Therefore, non-trial patients with 
metachronous metastases could not be included in the analysis. All stage IV 
colorectal cancer patients who were diagnosed during the CAIRO trial accrual 
period and who received chemotherapy were identified in the NCR.  
 
Comparison of trial with non-trial patients 
For reasons mentioned above, the comparison was restricted to stage IV 
patients. To compare the outcome between trial and non-trial patients, non-
trial patients were identified. For a more detailed analysis, 29 hospitals were 
selected which were considered to be representative for Dutch healthcare (3 
university hospitals, 14 large teaching hospitals, and 12 general hospitals). This 
was further checked by comparing the median overall survival of all stage IV 
patients in these 29 hospitals with all other patients identified by the NCR. Of 
these 29 hospitals, 26 hospitals participated in the CAIRO trial. The medical 
files of all stage IV colorectal cancer patients who received chemotherapy 
outside the CAIRO trial in these 29 hospitals were reviewed. Data were 
collected on baseline characteristics, CAIRO eligibility criteria, treatment 
schedule, and survival. These data were compared with data from stage IV 
patients included in the CAIRO trial. Trial participation was assessed by 
comparing the number of patients included in the CAIRO trial with the Figure 1: 
Flow chart of the 4200 patients who were diagnosed w ith stage IV colorectal cancer 
during the CAIRO trial accrual period. 
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total number of patients who did not participate but would have been eligible 
for the CAIRO trial.  
 
Statistics 
Baseline patient characteristics of trial versus non-trial patients were compared 
using the Students t-test for continuous variables and  χ2 test for dichotomous 
or nominal values. Overall survival was calculated in all patients from the date 
of diagnosis until death or censored on the date last known to be alive. This 
was done to allow a fair comparison of trial versus non-trial patients. Of note, 
the overall survival in the CAIRO trial was originally calculated from the date 
of randomisation.  
The median overall survival was estimated using the Kaplan-Meier method, and 
trial patients were compared to non-trial patients by means of the logrank test. 
Multivariable analysis was performed with the Cox-Proportional Hazards Model. 
The analyses were performed with SPSS statistical software (version 18). All 
statistical tests were 2-tailed, using a 5% significance level.  
 
During the accrual period of the CAIRO trial, 4200 patients were registered by 
the NCR with stage IV colorectal adenocarcinoma, of whom 1946 patients 
received palliative chemotherapy (Fig. 1). Of these, 396 patients were included 
in the CAIRO trial, 30 patients in other ongoing trials, and 1520 patients 
received chemotherapy outside the scope of trials. Of the 2254 patients who 
did not receive chemotherapy, 838 patients did not receive any treatment, 
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1322 patients had a resection of the primary tumour of whom 141 patients also 
had a metastasectomy, and 94 patients were treated with radiotherapy. 
In the 29 selected hospitals, the NCR identified 558 stage IV CRC patients who 
received chemotherapy, of whom 162 patients were included in the CAIRO trial 
and 396 patients received chemotherapy outside the trial. The median overall 
survival in these 396 patients from these 29 hospitals did not significantly differ 
from the total of 1120 patients with stage IV disease who have received 
chemotherapy as identified by the NCR (data not shown), supporting the 
representability of the 29 hospitals. After review of the medical files of these 
396 patients, 224 patients were identified who fulfilled all eligibility criteria 
for the CAIRO trial and therefore could have been included in this trial. Of the 
remaining 172 patients, 85 patients did not meet the trial eligibility criteria and 
87 patients were not included in this analysis because of missing files. In 91 of 
the 224 eligible non-trial patients, the actual baseline performance status was 
not scored in the files, but was considered to be within the limits of the CAIRO 
inclusion criteria based on descriptive data in the patient files. 
 
Reasons for non-participation of the 224 eligible non-trial patients were patient 
refusal (47 patients), treatment in non-participating hospital (50), logistical 
reasons (13), possible metastasectomy considered (8) and unknown (106). 
Reasons for non-eligibility in 85 patients were (more than one reason possible 
per patient): poor performance status (44), serious comorbidity (16), laboratory 
abnormalities (12), second malignancy in the past 5 years (10), no evaluable 
disease parameter (7), CNS metastases (3), and other reasons (12).   
 
Outcome of trial versus non-trial patients 
Baseline characteristics of the 224 non-trial patients who fulfilled all eligibility 
criteria of the CAIRO trial were comparable to the 394 eligible trial patients 
(Table 1). The 85 ineligible non-trial patients had a significantly worse 
performance status, more often an increased alkaline phosphatase and less 
often had a resection of their primary tumour.  
First-line treatment of the 224 eligible non-trial patients consisted of 
fluoropyrimidine monotherapy in 130 patients (58%) and combination 
chemotherapy in 94 patients (42%). By randomisation this was 50%-50% in the 
CAIRO trial. Eligible non-trial patients receiving first-line monotherapy were 
significantly older compared with patients receiving first-line combination 
therapy, with a mean age of 64 versus 58 years, respectively (p<0.0001). There 
was no difference in the number of cycles in first line treatment between the 
eligible non-trial patients (7.2 (95 %CI 6.2-8.2) and trial patients (7.8, (95 %CI 
7.2-8.4 ). None of the patients received bevacizumab or epidermal growth 
factor receptor antibodies in first-line treatment since these drugs were not 
yet available during the study period.  
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Figure 2: Overall survival for stage IV colorectal cancer patients participating to the 
CAIRO trial (n = 394), and patients who were treated outside trials and did (n = 224) 
or did not (n = 85) meet CAIRO eligibility criteria. 
 
 
 
The median overall survival of eligible stage IV non-trial patients and stage IV 
trial patients was 15.7 months and 17.0 months from the date of diagnosis, 
respectively (p=0.7, HR 1.03, 95% CI(0.87-1.23) (Figure2). Median overall 
survival of ineligible non-trial patients was 9.3 months, which was significantly 
worse when compared to trial patients (p <0.01, HR 1.70, 95% CI 1.33-2.17). 
Median overall survival of patients not receiving any chemotherapy (n=2254) 
was 4.5 months (95% CI 4.1-4.9). The median age in this patient group was 
significantly higher (72 years, range 29-96). In a Cox proportional Hazards model 
with WHO performance status, number of metastatic sites, resection of the 
primary tumour, location of the primary tumour, serum LDH, and serum alkaline 
phosphatase, we did not observe a significant difference in overall survival 
between eligible non-trial and trial patients (HR 1.1, 95 % CI 0.98-1.25). 
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Trial participation 
With 1946 non-trial stage IV colorectal cancer patients treated with 
chemotherapy identified during the trial accrual period and 394 stage IV 
patients actually included in the trial, the trial participation to the CAIRO trial 
was 20%. In addition, 30 patients were treated during the same period in trials 
other than CAIRO. Thus, overall trial participation during this period for stage 
IV cancer patients was 22%. When all diagnosed stage IV patients were 
considered the overall trial participation was 10%. 
 
We have compared the outcome in terms of overall survival between metastatic 
colorectal cancer patients treated within the scope of a clinical trial and 
patients treated outside this trial during the same period. A large Dutch 
multicentre phase III randomized trial (CAIRO) in metastatic colorectal cancer 
was used as the reference trial, which was performed within the framework of 
a cooperative group (DCCG) in approximately 80% of Dutch hospitals. In this 
trial the standard cytotoxic drugs for metastatic colorectal cancer were used 
at their normal doses and schedules, and standard entry criteria were used that 
are also applicable to the safe use of these drugs in daily practice. Moreover 
both arms of the trial were used in daily practice already. This use of standard 
treatments in both arms provided the opportunity to compare the outcome of 
trial patients with non-trial patients who were treated during the trial accrual 
period.  
We observed no difference in median overall survival between trial and non-
trial patients when non-trial patients were selected by trial eligibility criteria, 
but we found a significantly reduced overall survival in non-trial patients who 
did not meet these eligibility criteria. Several comments should be made on 
this result.  
Our analysis is restricted to patients with stage IV (i.e. synchronous) 
metastases, since the NCR only registers patients at primary diagnosis. 
Previously published data from the CAIRO study have shown a comparable 
survival for patients with synchronous as compared to patients with 
metachronous metastases, when only synchronous metastatic patients were 
considered in whom a resection of the primary tumour was performed [8].  In a 
subsequent study we provided arguments that the worse prognosis that is 
generally reported for synchronous metastatic patients may be attributed to 
the fact that in many of these patients a resection of the primary tumour is not 
performed [9]. This may explain the shorter median overall survival of the 
patients in this study as compared to the median survival in more unselected 
patients with both synchronous and metachronous metastases treated with 
chemotherapy. Since a significantly smaller percentage of non-eligible non-trial 
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patients had their primary tumour resected, this could have contributed to their 
worse outcome (table 1). However, since the absolute difference was relatively 
small, we do not consider this factor to be the only reason for the worse 
outcome of these patients. The worse PS of the non-eligible non-trial patients 
may also have been a relevant factor. In any case, the prognostic value of 
resection of the primary tumour has not been firmly established and is currently 
the subject of ongoing prospective phase III studies such as the CAIRO4 trial.  
Because of the straightforward design and the use of standard drugs for this 
indication, the conduct of the trial was easily feasible in all Dutch hospitals, 
and patient referral to specialized centres was therefore not required. 
Incentives such as access to experimental drugs with promising activity or high 
investigator fees were not applicable in this trial. Reasons for non-participation 
were retrospectively checked in the selected patient population, but it 
appeared that these data were not recorded in the files of the majority of 
patients.  
Several factors have been described that could influence whether a trial in 
comparison with daily care may have a positive or a negative effect on the 
outcome of patients [3]. A possible trial effect was hypothesised to be 
attributed to five possible factors: the therapy, the protocol, the care, the 
Hawthorne effect and a placebo effect. The authors of this systematic review 
concluded that, although the evidence was not conclusive and the available 
data were limited, it is more likely that participation in a clinical trial had a 
positive effect. The effect appeared largest in trials in which an already 
established and effective treatment was applied. However, given the fact that 
standard drugs and schedules were administered in both treatment arms of the 
CAIRO trial we do not believe that such an effect is present in our analysis. 
Neither can differences in care or placebo effect be considered as important 
factors to improve the outcome of this trial in comparison with daily practice. 
Other factors such as patient age, geographical and social barriers on clinical 
trial accrual have been described [10,11], but we did not investigate these 
factors in our study. 
The external validity of trial results has previously been a matter of concern 
[12]. However, the external validity of this trial is further supported by the fact 
that eligible patients in the trial and outside the trial together represented 
almost 70 % of the stage IV patients receiving chemotherapy as identified by 
the NCR during the trial accrual period.   
The CAIRO trial eligibility criteria involved no restrictions other than related to 
the safe use of standard chemotherapeutic drugs. Our finding of a significantly 
reduced overall survival in non-trial stage IV colorectal cancer patients who did 
not meet the trial eligibility criteria is a strong argument for the strict use of 
these criteria in general practice. Studies on the outcome of treatments in 
general practice, which are often initiated by healthcare authorities on (usually 
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expensive) drugs, should therefore always evaluate whether patients did meet 
the standard eligibility criteria for these drugs. The worse outcome of non-trial 
versus trial patients that have been reported by others [13] is most likely due 
to the fact that many non-trial patients did not meet the trial eligibility criteria.  
The large group of patients who did not receive any chemotherapy had a poor 
median survival of 4.5 months. This group was significantly older compared to 
the trial patients. Older patients are frequently underrepresented in cancer 
clinical trials [11]. However, many colorectal cancer trials have shown that age 
by itself does not indicate a worse outcome of systemic treatment [14]. The 
main outcome of our study is that trial results can only be expected in the 
general population if the same selection criteria are applied.  
 
Lastly, the CAIRO trial had a high participation rate of 20%. We consider it 
unlikely that trial participation rates differ between patients with synchronous 
and metachronous metastatic colorectal cancer. Our trial participation rate 
exceeds the commonly reported 5-14% in cancer trials [15], although these 
latter findings were not always restricted to patients actually receiving 
treatment as in our analysis. In a more selected population study a participation 
rate of 30 % [13] has been reported, which shows the possibility of a high 
participation rate in hospitals in which a protocol is available for the majority 
of patients. The simple and straightforward design of the CAIRO trial, its use of 
standard drugs and the clinically relevant study objective will likely have had a 
positive effect on trial participation.      
In conclusion, for stage IV colorectal cancer patients we did not demonstrate a 
difference in outcome between patients included in a clinical trial and patients 
treated during the same period outside that trial but who met the trial 
eligibility criteria. Patients treated outside the trial not meeting the eligibility 
criteria had a significantly worse outcome. These results strongly indicate that 
the external validity of trial results only applies when trial eligibility criteria 
are respected in general practice. This also implies that for patient groups not 
fulfilling the safety criteria of trials in which the efficacy of a certain drug 
regimen was demonstrated, the treatment results should be monitored and 
compared to the patient groups with the same characteristics not receiving the 
study drug (preferably in a randomised trial) in order to assess the risks and 
benefits of the drug regimen in these selected groups. Such policy may in the 
end reduce the costs of healthcare.                          
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Re: Generalizability of trial results to elderly medicare patients with 
advanced solid tumors 
 
With interest we have read the analysis of Dr. Lamont and colleagues on three 
chemotherapy regimens in two different settings, clinical trials vs usual care 
(17). Using SEER-Medicare data the authors conclude that clinical trials for 
advanced pancreatic cancer and lung cancers tended to correctly estimate 
survival for Medicare patients aged 65 to 74 years, but to overestimate survival 
for older Medicare patients. However, the authors did not check the eligibility 
of patients for the treatments administered. We have analysed this aspect, and 
found that this may statistically significantly impact the outcome of treatment. 
We compared the outcome of 394 metastatic colorectal cancer patients treated 
with standard cytotoxic drugs within a prospective phase 3 trial using standard 
safety eligibility criteria (18) versus 309 patients treated outside the scope of 
this trial but with the same drugs and during the trial accrual period (19). 
Patients treated outside the trial were divided into 2 groups: patients who 
would have qualified for trial participation (n=224), and patients who failed to 
meet relevant eligibility criteria(n=85). We found that the outcome of patients 
treated outside the trial but who could have qualified was comparable with the 
outcome of patients treated within the trial, 15.7 months and 17.0 months 
respectively (two-sided log-rank test, p=0.70; HR=1.03, 95%CI=0.87-1.23). 
However, the outcome of patients treated outside the trial who did not meet 
standard eligibility criteria was statistically significantly lower compared to 
eligible non-trial patients and trial patients, with median overall survival times 
of 9.3 months(95%CI=7.4-11.2), 15.7 months(95%CI=14.1-17.4), and 17.0 
months (95%CI=15.7-18.4), respectively (p<0.01, two sided log-rank test), 
figure 1. There was no statistically significant difference in age between these 
groups, 61 years for the eligible non-trial patients, 61 years for the trial patients 
and 63 for the non-eligible non-trial patients (p=0.28). We concluded that the 
external validity of trial results only applies when trial eligibility criteria are 
respected in general practice. Therefore, the finding of Lamont et al. (1) that 
trial results are not generalizable in the older patient population may possibly 
be explained by the fact that these patients are not eligible for trials on criteria 
other than age. We strongly recommend to include the assessment of standard 
baseline safety criteria in population-based studies on the outcome of systemic 
treatments in cancer patients in daily practice. 
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Figure 1 Overall survival for stage IV colorectal cancer patients participating in the 
CApecitabineIrinotecanOxaliplatin (CAIRO) trial and patients who were treated 
outside trials and did or did not meet CAIRO eligibility criteria (two-sided log-rank 
test). 
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Introduction 
Performance status (PS) is an established prognostic factor in patients with 
advanced cancer, and is usually scored by the treating physician. The EORTC 
QLQ-C30 questionnaire as reported by cancer patients is a validated tool to 
assess quality of life(QoL). Subjectivity plays a role in both assessments, and 
data on a direct comparison are scarce. 
 
Methods 
We compared the prognostic value for overall survival (OS) of the WHO PS to 
the baseline physical function scale of the EORTC QLQ-C30 (QLQ-C30PF) in a 
prospective randomised phase 3 trial in metastatic colorectal cancer, the CAIRO 
study. Patients were divided into 2 groups based on the baseline QLQ-C30PF. 
QLQ-C30PF  was considered “good” if the score was more than 66.7% and  
“poor” if  66.7% or less. Results were validated in a subsequent phase 3 study 
in mCRC, the CAIRO2 study. 
 
Results 
The median OS for patients with a “good” QLQ-C30PF and a “poor” PF in  
patients with WHO PS 0, was  20.3 months (n=300) and 10.4 months (n=44), in 
patients with  WHO PS 1  16.8 months (n=125) and 10.1 months (n=63), and in 
patients with  WHO PS 2 16.2 months (n=11) and  9.9 months (n=12), 
respectively.  In a Cox regression model which included other prognostic 
factors, “good” versus “poor” QLQ-C30PF was significantly prognostic for 
overall survival (0.57 95%CI 0.46-0.72), but not WHO PS. These results were 
confirmed in the CAIRO2 study. 
 
Conclusions 
We demonstrate in mCRC patients that PF, as assessed by patients using the 
EORTC QLQ C-30, is superior in terms of prognostic value to WHO PS as scored 
by physicians. Our data support to include the results of baseline EORTC QLQ-
C30PF instead of WHO PS as a stratification parameter in oncology trials.  
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Assessment of the performance status (PS) is an important tool for physicians 
to evaluate physical functioning of patients.  In clinical oncology it is widely 
used to decide which patients are physically suitable for treatment. It is an 
established prognostic factor for survival (20), and  therefore frequently used 
as a stratification parameter in randomised clinical trials. Various scoring 
systems of PS are used:  Karnofsky introduced the first performance score in 
1948 (21). In 1960 the Eastern Co-operative Oncology Group(ECOG) PS scale was 
introduced(22), which is more simple and has a better predictive validity (23). 
This was later adapted to a scale of 6 points, which is currently known as the 
ECOG PS or WHO PS score. Obviously, subjective factors may play a role in the 
assessment of the PS of the patient by the physician, and the quality of this 
assessment may vary(20). 
The current standard of patient-centred care has resulted in more attention to 
Patient Reported Outcomes (PROs). These PROs are increasingly considered as 
important measures to assess the effects of treatment in terms of toxicity and 
well being as compared to outcome as assessed by physicians(24). The 
prognostic value of PROs has recently been studied in several tumour types (25-
27). The quality of life (QoL) questionnaire (QLQ) C30 of the EORTC is one of 
the most frequently used  questionnaires to assess PRO  in oncology clinical 
trials. The QLQ-C30 is divided in global health status/QoL, functional scales and 
symptom scales items.  
A cross-validation of the Karnofsky PS and the QLQ-C30 (28) showed that 
Karnofsky PS only reflects physical functioning, whereas the QLQ-C30 reflects 
a greater scope of physical functioning by also including the symptoms of pain, 
breathing and fatigue as well as non-physical functioning concerning social, 
emotional, and cognitive well-being. In the phase 3 CAIRO study of the Dutch 
Colorectal Cancer Group (DCCG) (18) in patients with advanced colorectal 
cancer (ACC) we noted a discrepancy within several patients between the 
specific physical functioning scores of the QLQ-C30 (QLQ-C30PF) as reported by 
patients and the WHO PS as scored by physicians, while these items in principle 
should have a similar result.   
We therefore performed an overall comparison on the prognostic value in terms 
of overall survival (OS) between the WHO PS as assessed by the treating 
physicians and the  baseline QLQ-C30 PF  as reported by patients. We then 
validated our results in a subsequent phase 3 study in mCRC, the CAIRO2 
study(5). 
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Study design 
We retrospectively compared the prognostic value for median OS of the WHO 
PS as reported by the treating physicians with the QLQ-C30PF as reported by 
patients. 
 
Patient population 
Metastatic colorectal cancer patients who participated in the randomised phase 
3 CAIRO trial were used for this analysis, Clinical Trials.gov NCT00312000(18). 
In this trial, 820 previously untreated mCRC patients were randomised between 
2 arms: 1) sequential treatment with capecitabine, irinotecan, and 
capecitabine plus oxaliplatin, and 2) upfront combination treatment with 
capecitabine plus irinotecan followed by capecitabine plus oxaliplatin. 
Stratification parameters included WHO PS (0-1 versus 2), prior adjuvant 
treatment (yes versus no), serum LDH value (normal versus abnormal), 
predominant localisation of metastases (liver versus extrahepatic), and 
treatment centre. The primary endpoint was OS, secondary endpoints included 
QoL. The final results did not show a significant difference in median OS 
between the two treatment arms. QoL evaluation was a prospective part of the 
study, which for financial reasons was limited to the first 635 patients that were 
included in the study. All patients who completed a baseline QoL questionnaire 
were included in this analysis.   
We validated our results in the CAIRO2 study, in which the addition of 
cetuximab to a regimen of capecitabine, oxaliplatin and bevacizumab was 
investigated in mCRC patients , Clinical trials.gov NCT00208546(5).  CAIRO2 
included patients with WHO PS 0-1, and baseline QLQ-C30 was also a 
prospective part of the study.  
 
Measures 
Both CAIRO and CAIRO2 study required the assessment of WHO PS by the 
treating physician of all patients prior to randomisation (Table 1). Patients were 
asked to complete the baseline EORTC QLQ-C30(29) questionnaire prior to 
randomization and every 3 cycles thereafter until disease progression.  For the 
current analysis we used the baseline scores of the answers to the 5 questions 
of the QLQ-C30 PF (Table 2). Other scores of the QLQ-C30 were not analysed. 
We classified patients as having poor physical functioning   when 3 or more 
questions were answered with “quite a bit” or “very much”. Patients who did 
not meet this criterion were classified as having good physical functioning. With 
the formula of the EORTC QLQ-C30 PF scores were calculated according to the 
EORTC QLQ-C30 manual(30).  By this calculation  a good score should then be 
more than 66.7% and a poor score 66.7% or less. The scores of the physical 
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functioning were then used to divide patients for each of the 3 WHO PS groups 
(0, 1 and 2) into two groups: those with either “good” or “poor” QoL PF, 
resulting in a total of 6 groups.  
 
Statistics 
OS was estimated using the Kaplan-Meier method and was compared using the 
log-rank test.  All tests were 2-sided with an alpha of 5 %. A multivariable Cox-
regression model was used to test which scoring system had a better prognostic 
value, WHO PS or QLQ-C30PF. The other variables entered in this model were 
the factors  that were found prognostic in the retrospective analysis of the 
CAIRO study: serum LDH (normal vs elevated), number of metastatic sites (1 vs 
more than 1), resection of the primary tumour, and treatment arm (18, 31).  
The same method and analysis was performed in the CAIRO2 trial. All analyses 
were performed using STATA 13.1.  
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WHO Performance Status 
0 Able to carry out all normal activity without restriction 
1 Restricted in physically strenuous activity but ambulatory and able 
to carry out light work 
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair 
5 Dead 
Table 1. WHO Performance status 
 
 
 
 
 
 
EORTC QLQ-C30 (version 3.0.) Not at 
  All 
   A 
Little 
Quite 
a Bit 
Very 
Much 
1. Do you have any trouble doing strenuous 
activities, like carrying a heavy shopping 
bag or a suitcase? 
 
  1 
 
  2 
 
  3 
 
  4 
2. Do you have any trouble taking a long 
walk? 
 
  1 
 
  2 
 
  3 
 
  4 
3. Do you have any trouble taking a short 
walk outside of the house? 
 
  1 
 
  2 
 
  3 
 
  4 
4. Do you need to stay in bed or a chair 
during the day? 
 
  1 
 
  2 
 
  3 
 
  4 
5. Do you need help with eating, dressing, 
washing yourself or using the toilet? 
 
  1 
 
  2 
 
  3 
 
  4 
Table 2. Physical functioning items of the EORTC QLQ-C30 
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A total of 556 patients included in the CAIRO trial completed a baseline QoL 
form. One patient had to many PF items missing therefore 555 patients were 
eligible for this analysis. Patients with WHO PS 0, 1 and 2 had a median OS of 
18.9, 14.7, and 12.9 months, respectively (p<0.001, Fig. 1). Patients with 
“good” and “poor” QLQ-C30PF had a median OS of 19.3 and 10.2 months, 
respectively (p<0.001, Fig. 2).  Next, we combined the results of WHO PS and 
QoL scores (Table 3). The median OS for patients with a “good”  versus a “poor”  
QLQ-C30PF  of patients with a WHO PS 0 was 20.3 months (n=300) and 10.4 
months (n=44), respectively.  For patients with WHO PS 1, this was16.1 months 
(n=126) and 10.1 months (n=63), respectively, and for patients with WHO 2 16.2 
months (n=11) and 9.9 months (n=12)respectively (Table 3, Fig 3).   
 
In a multivariable Cox regression model which included baseline serum LDH, 
number of metastatic sites, resection status of the primary tumour and 
treatment arm, a “good” versus “poor” QLQ-C30 PF score was significantly 
prognostic for OS (HR 0.57 (95%CI 0.46-0.72) as was serum LDH  with a HR of 
0.56 (95%CI 0.46-0.67), but not WHO PS (WHO PS 0 vs 1 HR 0.85, 95%CI 0.69-
1.02; WHO PS 0 vs 2 HR 0.87, 95%CI 0.54-1.39, Table 4).  
 
 
 
 
 
 
 
 
 
 
WHO 
PS 
QLQ-C30 
PF 
Total N 
(%) 
Median OS 
(months) 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
0 Good QoL 300 (54%) 20.3 18.2 21.9 
Poor QoL 44   (8 %) 10.4 6.5 17.1 
1 Good QoL 125 (23 %) 16.8 14.0 19.8 
Poor QoL 63   (11 %) 10.1 6.6 12.2 
2 Good QoL 11   (2 %) 16.2 4.6 23.1 
Poor QoL 12   (2 %) 9.9 3.6 22.2 
Table 3 Overall survival for patients with good versus poor QoL within the subcategories 
of patients with WHO 0 ,1, and 2. 
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Table 4 Multivariable Cox regression model for overall survival  
 
 
In the CAIRO2 trial 699 of the 755 randomised patients completed a baseline 
QoL form. Patients with WHO PS 0 and 1 had a median OS of 22.2 and 17.1 
months, respectively (p=0.004).  Patients with “good” and “poor” QLQ-C30PF 
had a median OS of 22.0 and 15.2 months, respectively (p < 0.001). The median 
OS of patients with a “good”  versus a “poor” QLQ-C30PF in the group of 
patients with WHO PS 0 was 23.5 months (n=377) and 18.9 months (n=183), 
respectively, and in the group of patients with WHO PS 1  17,1 months (n=61), 
and 14.2 months (n=78), respectively (Table 5.).  In a multivariable Cox 
regression model which included the same variables as in the CAIRO analysis, a 
“good” versus “poor” physical functioning was significantly prognostic for OS 
(HR 0.68 (95%CI 0.55-0.84), but not WHO PS (WHO PS 0 vs 1 HR 0.89, 95%CI 
0.74-1.07, Table 6). 
 
 
 
WHO PS QLQ-
C30PF 
Total N Median OS 
months 
95% Confidence Interval 
Lower Bound Upper Bound 
0 Good  377 (54 %) 23.5 21.7 25.9 
Poor  61   (9 %) 17.1 12.0 22.0 
1 Good  183 (26 %) 18.9 16.4 21.3 
Poor  78   (11 %) 14.2 10.9 17.4 
Table 5 Overall survival for patients with good versus poor QoL within the subcategories 
of patients with WHO 0 and 1 in the CAIRO2 study  
 
 
 
Variables HR 95 % CI p-value 
Serum LDH normal vs elevated 0.56 0.46-0.67 0.000 
QLQ-C30PF good vs poor 0.57 0.46-0.72 0.000 
Number of metastatic sites 1 vs >1 0.72 0.61-0.87 0.001 
WHO PS  0 vs 1 0.85 0.69-1.0.2 0.09 
              0 vs 2 0.87 0. 54-1.39 0.56 
Resection primary tumour (yes vs no) 0.76 0.61-0.95 0.02 
Treatment arm ( sequential vs 
combination chemotherapy) 
0.92 0.77-1.1 0.36 
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Table 6 Multivariable Cox regression model for overall survival in the CAIRO2 study 
 
 
 
 
 
Figure 1: Overall survival for WHO PS 0 (median 18,9 months, 95% CI 17,3-21.0,7), 1 
(median 14,7 months, 95% CI 12,2-17,3) and 2 (median 12,9 months(95% CI 4,2-21,6) 
  
Variables HR 95 % CI p-value 
Serum LDH normal vs elevated 0.68 0.57-0.81 0.001 
QoL good vs poor 0.68 0.55-0.84 0.000 
Number of metastatic sites 1 vs >1 0.72 0.59-0.87 0.001 
WHO PS  0 vs 1 0.89 0.74-1.07 0.21 
Resection primary tumour (yes vs no) 0.80 0.64-1.00 0.05 
Treatment arm (CB vs CBC) 0.85 0.72-1.01 0.074 
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Figure 2 Overall survival for ‘good’ QoL (median 19,3 months, 95% CI 17.9-20.5)vs ‘poor’ 
QoL (median 10.2 months, 95%CI 8.5 12.2). 
 
 
 
Figure 3. Overall survival of WHO PS and ‘good’ QoL vs ‘poor’ QoL.  
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The CAIRO study investigated the optimal use of standard chemotherapy 
regimens in patients with mCRC. During the analysis of the data from this study, 
we sometimes observed a discrepancy between the WHO PS as scored by 
physicians and  the 5 physical functioning items from the EORTC QLQ-C30 as 
scored by patients. For example, a patient with a WHO PS score of 0 reported 
that he had quite a bit trouble taking a short walk. Therefore we performed an 
overall comparison  of physician- versus patient-reported physical performance 
in relation to the median OS. Although WHO PS and QLQ-C30PF each showed a 
significant difference in median OS between their respective subgroups, QLQ-
C30PF but not WHO PS was a significant prognostic factor in multivariable 
analysis. These results were confirmed in the CAIRO2 study.  
The clinical relevance of this finding is that within each category of patients 
with WHO PS 0, 1 and 2, a large difference in median OS was observed between 
patients with a good and a poor QLQ-C30 PF. For instance, 13% of patients (44 
out of 344) with a WHO PS score of 0 had a poor QLQ-C30PF, and had a worse 
survival as compared to the 66% of WHO PS 1 patients with good QLQ-C30PF. 
QLQ-C30 PF was also a relevant discriminating factor within the group of 
patients with PS1 and PS2, although within the latter category the number of 
patients was small. Therefore, our results show a better prognostic value for 
PRO concerning physical functioning as measured by the physical functioning 
scale of the EORTC QLQ-C30 compared to the physician-rated WHO PS. Patients 
with both WHO PS 0 or 1 and good QLQ-C30 PF had the best survival, while 
patients with a WHO PS 0 but a poor QLQ-C30 PF had comparable survival to 
patients with a WHO PS 2. The prognostic value of serum LDH was comparable 
to QLQ-C30 PF 0, with a HR of 0.56 (95%CI 0.46-0.67). We have confirmed these 
results in the CAIRO2 study for patients with WHO PS 0 and 1 by multivariable 
analysis. 
PROs were found to be prognostic in several other studies (27, 32-35). Gotay et 
al. systematically assessed the impact of various PROs on patient survival in 39 
clinical trials in different tumour types and concluded that PROs might be 
considered for stratification purposes in future trials, as they were often better 
predictors of survival than PS. Quinten et al. (27) assessed prognostic 
significance of socio-demographic and clinical variables and the QLQ-C30 with 
Cox proportional hazard models in a meta-analysis of 30 different trials also in 
different tumour types. They found physical functioning, pain and appetite loss 
to be prognostic in addition to socio-demographic and clinical measures. 
Efficace et al. (26) showed that social functioning as measured by the social 
functioning scale of the EORTC QLQ C-30, acted as an important prognostic 
measure for survival beyond a number of previously known biomedical 
parameters in metastatic colorectal cancer(26). Since we analysed the 
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prognostic value of physician versus patient assessed physical performance, we 
only used the questions of the physical functioning part of the QoL-C30, because 
we considered these questions as the best surrogate for WHO PS.  
An important limitation of scoring PS and QLQ-C30 PF remains their subjective 
nature, which may occur at the side of both the physician and the patient. 
Blagden et al. studied the agreement in assessment of the ECOG performance 
status among patients and their physicians (36). Physicians were more likely to 
assign a better score to patients than patients did to themselves. This was 
confirmed by Schnadig et al.(37). However, these subjective parameters can 
be validated by objective outcome measures such as OS. Although we and 
others show that PS assessed by patients and physicians is significantly 
associated with survival, our data strongly support the superiority of patient-
reported baseline QoL to physician-assessed WHO PS.  
In conclusion, physical functioning as assessed by patients using the EORTC QLQ 
C-30PF is more prognostic than WHO PS as scored by physicians. Our data 
suggest to include the results of baseline physical functioning of the EORTC QLQ 
C 30 PF instead of WHO PS as a stratification parameter in oncology trials.  
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Background.  
High quality clinical trials are essential for further improvement of treatment 
strategies for prolonged survival and reliable evidence-based outcomes. 
However, there are no defined standards for the quality of clinical trial 
performance. The aim of this study is to examine and compare clinical trial 
performance with a composite score between (different types of) hospitals, to 
identify potentially predicting factors for a high trial performance and examine 
a learning curve in composite performance scores between early compared to 
subsequent included patients. 
 
Methods. 
We evaluated trial performance in three large phase 3 randomized clinical trials 
in metastatic colorectal cancer (CAIRO studies of the Dutch Colorectal Cancer 
Group, total n=2131) with a newly introduced composite score, consisting of 
stratification errors, major protocol violations, number of included ineligible 
patients, and reporting of serious adverse events (SAE) on hospital and patient 
level. These data were supplemented with a hospital survey containing 
questions about number of beds, oncologists and research nurses. Composite 
scores were compared between early (first 3 patients) and subsequent patients. 
A logistic regression was performed to identify factors associated with better 
trial performance (3-4 points). 
 
Results. 
We observed variation in trial performance between 84 participating hospitals. 
However, no differences in performance between hospital categories 
(university, teaching, regional hospitals) were identified and none of the 
examined variables could be linked to a high composite performance score. In 
top 10 ranking hospitals with highest inclusion rates, trial performance on 
patient level was significantly lower in the first three inclusions compared to 
subsequent patients. 
 
Conclusions.  
Trial performance was comparable between different types of hospitals and no 
factors were able to predict a high composite trial performance score. In the 
highest including hospitals we identified a learning curve for trial performance. 
We therefore recommend increased support during the first patient inclusions 
in participating centers in order to improve trial performance. Our composite 
score could be used as a quality metric for trial performance for individually 
based hospital evaluation. 
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Survival in metastatic colorectal cancer has improved substantially over time, 
which is for a large part due to the availability of more effective systemic 
therapies.(38, 39) Clinical trials are essential in this process, and will be 
necessary for further improvement of treatment. Maintaining high quality 
within these trials is a requisite for reliable evidence-based outcomes. 
However, even in the presence of guidelines for the standard of care, there are 
no defined standards for the quality of clinical trial performance. 
 
Quality assurance of clinical trials is a complex issue. Several factors 
contributing to a good performance can be identified (13), such as the 
requirement for adequate methodology and protocols in order to maintain 
reliability and validity of the obtained results. However, data on the level of 
protocol adherence are scarce. Multi-centre trials , especially if they are 
complex, may lead to variability in treatment and data collection. To prevent 
biased results and to maintain integrity of the data, trial protocols need to be 
followed as closely as possible. Quality assurance is therefore a prerequisite. 
 
Although no validated indicators for clinical trial performance are available, a 
potentially useful criterion for clinical trial adherence may be the number of 
protocol deviations or protocol violations. Protocol deviations are not caused 
or preventable by the investigator, in contrast to protocol violations. 
Therefore, the number of protocol violations may be used to assess and 
compare (investigator) trial performance.(40) Major protocol violations are 
defined as deviations, which may result in harm to the patient and may impact 
the integrity of data. These violations may have major impact on data 
interpretation and may result in the assumption of wrong recommendations.(40, 
41) Protocol violations are usually underreported and differs widely among 
studies.(41) 
 
The number of study participants included per participating hospital in 
multicenter trials is earlier suggested as a potential indicator of trial 
performance.(42) However, this finding prompted several comments that 
agreed(43, 44) and disagreed with this indicator(45, 46). Also conflicting results 
regarding trial performance between different types of hospitals have been 
reported.(42, 47, 48) In case of any reported difference in performance, there are 
no data on the underlying contributing causes. Therefore, the aims of our study 
are: 1) to examine clinical trial performance of hospitals that participated to 
national phase 3 studies in metastatic colorectal cancer using a scoring system 
based on stratification errors, major protocol violations, serious adverse event 
(SAE) reporting and the number of ineligible patients that was included; 2) to 
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identify factors that may explain differences, if any, in clinical performance 
between different hospital categories; 3) to compare clinical trial performance 
between hospitals with low and with high accrual rates; and 4) to examine 
whether a learning curve can be identified per hospital between early included 
patients compared to subsequent included patients in the trial. 
 
 
Data from three large phase 3 randomized clinical trials in metastatic colorectal 
cancer were pooled for this study: CAIRO [NCT00312000](4), CAIRO2 
[NCT00208546](5), and CAIRO3 [NCT00442637](6). The Dutch Colorectal Cancer 
Group (DCCG) was the sponsor of all studies, and a total of 84 hospitals 
participated. Of the participating hospitals 43 (51%) were regional hospitals, 32 
(38%) teaching hospitals, 8 (10%) university hospitals, and 1 cancer institute. 
We have added the latter to the university hospitals group in all analyses. For 
all 3 studies, regional initiation meetings were organized, and accrual was only 
allowed in hospitals of which relevant staff had been present at these meetings. 
 
The primary outcome of our study was trial performance, consisting of a 
composite of 4 dichotomous items: 1) number of errors during stratification 
(cut-off 10%); 2) number of major protocol violations (cut-off 10%); 3) number 
of included ineligibles (cut-off 5%), and 4) reported serious adverse events (SAE) 
within 7 days (cut-off 75%). For all 4 items a participating hospital could gain 1 
point: the composite score ranges between 0 and 4 per participating hospital 
per study. A higher score indicates a better trial performance. The cut-off 
scores are based on relevance for clinical practice: therefore the cut-off value 
for ineligibles is for example lower than the cut-off value for stratification 
errors, as ineligibility is expected to be more harmful than a stratification error. 
All data regarding the primary outcome were collected prospectively during the 
trials. To compare hospitals with low and high accrual rates, scores were 
compared for sites with low (less than 5 patients) and high (5 or more patients) 
accrual. To identify variations in trial performance between early and later 
patient inclusions per hospital (learning curve), we labeled the first 3 included 
patients in the top-10 hospitals with highest inclusion rates as ‘early included’ 
and subsequent patients as ‘later included’. An adjusted composite score of 3 
dichotomous items (stratification errors, major protocol violations and 
ineligibility) was calculated at patient level, SAE reporting was excluded since 
SAE’s may occur at any time during the course of the study and therefore may 
not be a valid measurement to identify a learning curve. 
A questionnaire was sent to local investigators of participating hospitals to the 
CAIRO3 study during its conduct (March 2008), which consisted of the following 
items, which were to be scored per hospital: the number of beds, the full-time 
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equivalence (FTE) of medical oncologists, the number of hours per week of a 
research nurse and the number of newly diagnosed patients with colorectal 
cancer per year. 
Data from the questionnaires were entered into an electronic database and 
merged with the data of the primary outcome per participating hospital per 
study. Characteristics of participating hospitals were compared between the 
three categories of hospitals. Categorical variables were analyzed using chi-
squared testing, or fisher’s exact test if appropriate. Continuous variables were 
compared between groups Kruskall-Wallis analysis. The primary outcome and 
its individual components were tested against the three hospital categories 
using a chi-squared test. An univariable en multivariable logistic regression 
analysis was performed to identify factors associated with a higher composite 
performance score and additionally univariable logistic regression was 
performed on the individual components of the composite score. All analyses 
were performed for all 3 trials combined as well as for each individual trial. All 
tests were two-sided and a p-value of <0.05 was considered to be statistically 
significant. 
 
Overall, 84 Dutch hospitals participated in one or more CAIRO studies. A total 
of 66 hospitals participated in the CAIRO study (total included patients; n=820), 
73 hospitals in the CAIRO2 study (n=755), and 61 hospitals in the CAIRO3 study 
(n=556). The response rate to the questionnaire was 45% (38/84). The 
characteristics of participating hospitals are shown in Table 1.  
 
The median inclusion of patients was significantly different between categories 
of hospitals in the total dataset with a median inclusion of 12 patients in 
university hospitals, 11 in teaching hospitals and 7 in regional hospitals (p 
<0.01). Furthermore, in each study the median inclusion in university, teaching 
and regional hospitals was 14, 18 and 7 patients (p <0.05) in CAIRO, 12, 13 and 
7 patients (p < 0.05) in CAIRO2, and 7, 7 and 8 patients in CAIRO3 (p=0.91), 
respectively (Table 1). The median overall composite performance score was 2 
(IQR 2-3) which was not significantly different between categories of hospitals: 
university 2 (IQR 2-3), teaching 2 (IQR 1-3) and regional 2 (IQR 2-3). The median 
overall composite performance score was 3 (IQR 2-3) for hospitals including less 
than 5 patients, and 2 (IQR 1-3) for hospitals including 5 patients or more (p 
<0.01). 
In Figure 1, the mean composite performance score is plotted against the 
median inclusion rates for the different types of hospitals for CAIRO, CAIRO2 
and CAIRO3. In CAIRO and CAIRO2, the university hospitals had the highest 
score, but in the CAIRO3 study, regional hospitals scored highest. Twenty-one 
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hospitals that participated in at least 2 CAIRO studies, had a persisting low 
composite performance score (0-2 points). On the other hand, 6 hospitals had 
a persisting high performance score (3-4 points).  
Table 2 describes the univariable and multivariable analysis for factors that are 
potentially associated with a high composite performance score (3-4 points). 
The following were associated with the outcome: FTE oncologist (OR 1.15 per 
additional FTE; 95% CI 1.01-1.31), hours of research nurse (OR 1.01 per 
additional hour; 95% CI 1.00-1.02) and number of included patients (OR 0.19 for 
≥ 5 patients included; 95% CI 0.09-0.40). However, none of these variables 
remained significant after adjusting for all covariates listed in Table 2. 
 
Table 1. Characteristics of participating hospitals 
 
Variable   University 
hospitals 
Teaching 
hospitals 
Regional 
hospitals 
p-value 
Number of 
accruing hospitals 
CAIRO 7 26 33  
 CAIRO2 9 31 33  
 CAIRO3 7 27 27  
Accrual per hospital    
CAIRO 
 
Median 
(IQR) 
 
14 
(8-19) 
 
18  
(9-24) 
 
7 
(5-12) 
 
<0.05 
CAIRO2                                      Median
(IQR) 
12  
(8-16) 
13  
(8-16) 
7 
(4-10) 
<0.05 
CAIRO3                                        Median
(IQR) 
7 
(3-12) 
7 
(4-11) 
8  
(2-12) 
0.91 
Number of beds 
per hospital 
Median 
(IQR) 
882  
(715-1200) 
666  
(480-930) 
384  
(314-486) 
<0.05 
Number of hours 
research nurse per 
week per hospital 
Median 
(IQR) 
45  
(7-80) 
16  
(0-43) 
3  
(0-16) 
0.18 
Number of full-
time oncologists 
per hospital 
Median 
(IQR) 
9 (6-16) 3  
(2-4) 
2  
(2-2) 
<0.05 
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Figure 1. Mean composite performance score and the median inclusion for different 
types of hospitals in CAIRO, CAIRO2 and CAIRO3 
 
 
None of the examined variables could be linked to the individual components 
of the composite score, except for low and high inclusion rates as expected, 
since hospitals with less than 5 inclusions had a higher mean overall composite 
score than hospitals including 5 patients or more. Odds ratios were 0.36 (95% 
CI 0.18-0.72) for SAE reporting, 0.43 (95% CI 0.19-0.99) for major protocol 
violations and 0.34 (0.16-0.69) for stratification errors, respectively.  
 
The individualized patient composite scores in early included patients (first 3 
inclusions) were significantly lower compared to subsequently included patients 
(p <0.05). This learning curve was observed in the top-10 ranking hospitals with 
highest inclusion rates. 
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Table 2. Unadjusted and adjusted odds ratios (OR) with 95% Confidence Intervals (CI)  
for a higher (3-4 points) composite performance score.  
* adjusted for all variables listed.
Variable  OR (95% CI) OR (95% CI) 
 
 Unadjusted Adjusted* 
Hospital type  University reference reference 
 Teaching 0.55  
(0.21-1.39) 
0.70  
(0.07-6.67) 
 Regional 0.60  
(0.24-1.51) 
1.39  
(0.10-19.4) 
Number of beds  1.00  
(1.00-1.00) 
1.00  
(1.00-1.00) 
FTE oncologist  1.15 
(1.01-1.31) 
1.15 
(0.85-1.56) 
Hours of research nurse  1.01  
(1.00-1.02) 
1.00 
(0.98-1.02) 
Number of new metastatic 
colorectal patients per 
year 
11-20 patients reference reference 
Number of new metastatic 
colorectal patients per 
year 
 
21-30 patients 0.73  
(0.24-2.19) 
0.62 
(0.16-2.37) 
31-40 patients 1.84 
(0.51-6.70) 
2.23  
(0.49-10.2) 
41-50 patients 2.11 
(0.35-12.6) 
2.07 
(0.17-25.5) 
 >50 patients 0.84 
(0.21-3.44) 
0.57 
(0.06-5.23) 
Number of included 
patients (<5 or ≥ 5 
patients) 
 0.19  
(0.09-0.40) 
0.35 
(0.08-1.55) 
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We studied clinical trial performance in three large randomized clinical trials 
investigating treatment strategies in metastatic colorectal cancer. Based on a 
composite trial performance score including stratification errors, major 
protocol violations, SAE reporting and inclusion of ineligible patients, we 
identified a large variation in trial performance between hospitals. Inclusion 
rates were significantly higher in university and teaching hospitals compared to 
regional hospitals. However, we did not find a significant difference in trial 
performance between hospitals categories. There were no hospital-based 
factors identified (number of beds, FTE oncologist, hours of research nurses 
available), that could explain differences between hospitals with high or lower 
trial performance. Interestingly, hospitals with a low inclusion rate had a higher 
mean composite score compared to hospitals with a high inclusion rate. In the 
top-10 hospitals with highest inclusion rates, we observed a learning curve for 
trial performance. 
 
Our results are in line with earlier work by Begg et al.(47) They studied trial 
performance by rates of ineligibility, compliance with the protocol, and 
submission of data and concluded that the quality of participation of different 
types of hospitals was comparable. In agreement with their results, we 
observed no differences between type of hospitals using a composite endpoint 
that also included SAE reporting. However, we did identify a learning curve in 
hospitals with highest inclusion rates, an issue that was not addressed by Begg 
et al. We found a higher composite score for hospitals with a low accrual rate 
compared to hospitals with a high accrual rate. Although some studies showed 
lower performance scores for hospitals with low accrual rates(42), results of 
other studies did not show any correlation between accrual rates and clinical 
trial performance.(47, 49) This latter observation implicates that hospitals with 
low accrual rates, which are often regional hospitals, should not be excluded 
and may be even encouraged to participate in clinical trials.(48) 
 
In our study, we evaluated and compared trial performance between (different 
categories of) hospitals with a newly introduced composite score, because no 
scoring system for trial performance exists. However, the usability and validity 
of this score needs to be determined in follow-up studies. We were not able to 
explain the variation in our composite score between hospitals, even though we 
included data from three large clinical trials. This implies that, without proper 
validation, our composite score should be used with caution for comparison 
between hospitals. However, a possible implication for our composite score 
could be evaluation of trial performance per individual centre over time. This 
is supported by our finding of a learning curve for individual hospitals with a 
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high inclusion rate. An explanation for the learning curve could be an improved 
comprehension of and experience with the study protocol after inclusion of 
several patients. An important implication is to optimize support of 
participating hospitals during trials to prevent protocol deviations, with specific 
focus on the first patients included. 
Clinical trials are essential for improvement of treatment possibilities. High 
quality within these trials is a requisite for reliable evidence-based outcomes. 
There is a current need for an evidence-based instrument to evaluate trial 
performance between hospitals, possibly with an adjusted version of our 
composite score included. Evaluation and validation should be performed in 
different studies and research areas, to make it more widely applicable. 
 
In conclusion, trial performance, evaluated with a composite score including 
stratification errors, major protocol violations, SAE reporting and the inclusion 
of ineligible patients, was comparable between different types of hospitals. In 
the highest including hospitals we identified a learning curve for trial 
performance. Consequently, we recommend additional support during the first 
patient inclusions in every participating centre, to prevent stratification errors, 
ineligibility and major protocol violations. For individually-based hospital 
evaluation, our composite score could be used as a quality metric for trial 
performance.  
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Early and correct assessment of treatment-related mortality is highly important 
in cancer clinical trials. For a real-time knowledge of this crucial information, 
Serious Adverse Events (SAE) have to be reported within 24 hours. The SAE 
reports are collected centrally, assessed by the principal investigator(s) (PI) 
and/or study coordinators, and finally submitted to an independent data 
monitoring committee (IDMC). This system of early safety monitoring of clinical 
trials by the PI and IDMC largely depends on the early and reliable assessment 
of SAE reports. In Chapter 2 we assessed the quality of Serious Adverse Event 
(SAE) reporting. The study coordinators performed on site monitoring of the 
individual charts of all patients who died within 30 days of the last 
administration of study drugs, except if death was clearly caused by disease 
progression. All these deaths had been reported as SAE. The relationship 
between treatment and death was categorized as unrelated, remote, possible, 
or probable, and submitted to the IDMC of the study. Forty out of 112 patients 
who died within 30 days qualified for review. The relationship between cause 
of death and study drugs as initially reported by the local investigator was 
changed in 26 patients (65%). In 12 out of 14 patients with a probable 
relationship between cause of death and study treatment a major protocol 
violation (MPV) was identified. In addition to the MPVs, four patients were 
considered ineligible for study participation which was not detected after 
standard data processing. We concluded that there was little agreement 
between the local investigator and the IDMC concerning the relationship 
between death within 30 days of last study treatment and treatment itself, and 
that study treatment as a cause of death is frequently underestimated. This 
quality control showed that the assessment of SAEs can improve the quality of 
safety results.  
 
Discussion 
 
This process of on site monitoring of fatal serious adverse events by the study 
coordinators revealed relevant and new information, such as MPVs and patient 
ineligibilities, which was not detected by routine data management. Patients 
were included who did not fulfil the safety criteria for the study drugs, and/or 
dose adjustments were not performed when indicated as stated by the 
protocol. Severe toxicity occurred in these patients subsequently leading to 
death. These incidents underscore the importance of educating medical staff 
and patients. Feedback was provided to the local investigators, in order to 
improve local procedures and prevent unnecessary toxicity and treatment 
related deaths in the future. We recommend on site monitoring by experts for 
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fatal serious adverse events which are not clearly related to disease progression 
in addition to regular on site monitoring in oncology clinical trials. 
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Although not supported by solid evidence, it is generally thought that treatment 
of patients within the scope of a clinical trial may improve their outcome, for 
instance due to the fact that these patients receive more attention compared 
to patients who are treated outside clinical trials. In the CAIRO study, cytotoxic 
drugs were used at doses and schedules standard in daily practice, as were the 
eligibility and safety criteria. This allowed a comparison between trial patients 
and patients treated outside the trial.  
To achieve a timely completion of trials it is important to include as many 
patients as possible in a clinical trial. A commonly reported participation rate 
is 5-14 % in all cancer patients and 30 % in more selected populations. National 
data of the Netherlands Cancer Registry (NCR) made it possible to estimate the 
participation of colorectal cancer patients in trials during the inclusion period 
of the CAIRO trial. In Chapter 3 we compare the treatment outcome of patients 
with metastatic colorectal cancer included in this trial versus that of patients 
treated in daily practice. Stage IV colorectal cancer patients treated in the 
CAIRO trial were compared to patients treated the same way outside this trial 
in a representative selection of 29 Dutch hospitals during the trial accrual 
period in. Non- trial patients were identified by the NCR, and were checked for 
eligibility criteria of the CAIRO study. During the inclusion period 1946 stage IV 
colorectal cancer patients were registered in the NCR who received 
chemotherapy, of whom 394 patients were included in the CAIRO trial (20 %). 
We observed no difference in median overall survival between patients included 
in the clinical trial and eligible patients treated during the same period outside 
the trial in daily practice (HR 1.03, p=0.70). However, patients treated outside 
the trial who did not fulfil the standard eligibility criteria, but did receive 
comparable chemotherapy schedules had a significantly worse outcome (HR 
1.7, p < 0.01). We conclude that trial results can only be extrapolated to the 
general population if the same patient selection criteria are applied. We 
observed that 20 % of all patients with stage IV colorectal cancer receiving 
chemotherapy, participated in the CAIRO trial. When all diagnosed stage IV 
patients were considered the overall trial participation was 10 %. 
 
Discussion 
 
The external validity of trial results is a continuing matter of concern. We 
observed no difference in outcome between patients participating in a trial and 
those who were treated in daily practice during the same period with the same 
drugs and regimens and who met the trial eligibility criteria. This strongly 
supports the external validity of this trial. However, a significantly worse 
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outcome was observed in non-trial patients who were treated with the same 
chemotherapy but who did not meet these eligibility criteria. Our findings 
strongly caution against the use of cancer drugs in daily practice in patients 
who do not meet the eligibility criteria of the trial(s) in which the efficacy of 
these drugs was demonstrated. If these patients are being treated after all, 
careful monitoring of results is warranted. Validation of trial results for daily 
practice remains a matter of high priority. The currently ongoing observational 
cohort study in The Netherlands, the Prospective Dutch Colorectal Cancer 
Cohort (PLCRC), is a useful instrument to prospectively investigate treatment 
outcome in daily practice. This study will make it possible to assess the use of 
different therapies in daily practice and to compare the outcome to trial 
patients. It will also be a way to prospectively follow patients who do not fulfil 
the safety criteria and do receive a certain drug regimen.  
Our analysis also allowed the assessment of trial participation. The CAIRO trial 
had a high participation rate of 20% which exceeds the commonly reported 5-
14% participation rate in cancer trials. The simple and straightforward design 
of the trial, its use of standard drugs and the clinically relevant study objective 
will likely have had a positive effect on trial participation. 
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Performance status (PS) is an established prognostic factor in patients with 
advanced cancer, and is usually scored by the treating physician. The EORTC 
QLQ-C30 questionnaire as reported by cancer patients is a validated tool to 
assess quality of life. Subjectivity plays a role in both assessments, and data on 
a direct comparison are scarce. In Chapter 4 the prognostic value of the WHO 
performance status was compared with the physical functioning (PF) scale of 
the QLQ-C30 in a prospective randomised phase 3 trial in advanced colorectal 
cancer, the CAIRO study. Patients were divided into 2 groups based on the 
baseline physical functioning(PF) scales of the EORTC QLQ-C30. QoL was 
considered “good” if the PF score was higher than 66.7%. “Poor” QoL was 
defined as a PF scored 66.7% or less. The prognostic value in terms of median 
overall survival of both assessments was compared. Results were validated in 
the CAIRO2 study. The median OS for patients with a “good” QLQ-C30 PF and a 
“poor” PF in patients with WHO PS 0, was 20.3 months (n=300) and 10.4 months 
(n=44), in patients with WHO PS 1 16.8 months (n=125) and 10.1 months (n=63), 
and in patients with WHO PS 2 16.2 months (n=11) and 9.9 months (n=12), 
respectively. In a Cox regression model which included other prognostic factors, 
“good” versus “poor” QLQ-C30 PF was significantly prognostic for overall 
survival (0.57 95% CI 0.46-0.72), but not WHO PS. These results were confirmed 
in the CAIRO2 study. We concluded that patient reported QLQ-C30 PF was more 
prognostic than the physician reported WHO PS.  
 
Discussion 
 
The CAIRO study investigated the optimal use of standard chemotherapy 
regimens in patients with advanced colorectal cancer. During the analysis of 
the data from this study, we sometimes observed a discrepancy between the 
WHO PS as scored by physicians and the 5 physical functioning items from the 
EORTC QLQ-C30 as scored by patients at baseline. For example, a patient with 
an investigator assigned WHO PS score of 0 reported that he had quite a bit 
trouble taking a short walk.  
Therefore we performed an overall comparison of physician- versus patient-
reported physical performance in relation to the median OS. Within each group 
of the WHO PS we observed a large difference in QLQ-C30 PF. Patients with a 
WHO 1 and good QLQ-C30 PF had a better median overall survival than patients 
with WHO 0 and a poor QLQ-C30 PF. Other items of the QLQ-C30 such as social 
functioning have previously shown a prognostic value for OS. We used the 5 
physical functioning items of the QLQ-C30, because these items most optimally 
reflect the general health status of a patient. WHO PS is an established 
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prognostic factor and is often used as a stratification factor and an inclusion 
criterion. It has been observed in other studies that physicians are more likely 
to assign a better score to patients than patients do to themselves. We have 
validated these subjective measures by the objective outcome measure OS, and 
found the patient reported QLQ-C30 PF to be more prognostic than WHO PS as 
scored by physicians. We therefore recommend to include patient reported 
outcomes instead of physician-reported performance status as a stratification 
factor in clinical (cancer) trials. Obviously this should be done with an 
internationally accepted questionnaire, and the EORTC QLQ-C30 with 
translations and validations in 90 different languages appears to be a good 
option. 
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The quality of data that are derived from clinical trials is dependent of many 
factors. These include the requirement for adequate methodology and 
protocols in order to maintain reliability and validity of the obtained results. 
Although no validated indicators for clinical trial performance are available, a 
potentially useful criterion for clinical trial adherence may be the number of 
protocol violations. However, data on the level of protocol adherence are 
scarce. Major protocol violations are defined as deviations, which may result in 
harm to the patient and which may impact the integrity of data. The number 
of study participants included per participating hospital in multicenter trials 
has been suggested as a potential indicator of trial performance. Conflicting 
results regarding the influence of hospital type on trial performance have been 
reported. In Chapter 5 we report the evaluation of clinical trial performance 
with a composite score in three large phase 3 clinical trials with systemic 
treatment in colorectal cancer in The Netherlands. This score included 
stratification errors, major protocol violations, SAE reporting and the inclusion 
of ineligible patients. These data were supplemented with a hospital survey 
containing questions about the number of beds, medical oncologists and 
research nurses. Hospitals were divided into 3 categories: university-, teaching-
, and regional hospitals. Inclusion rates were higher in university hospitals and 
teaching hospitals compared to regional hospitals. A large variation in trial 
performance was observed between hospitals, but individual factors (number 
of beds, number of medical oncologists, presence of research nurse) could not 
be identified which could explain this variation. No difference in trial 
performance was found between the three hospital categories. Hospitals with 
a low accrual rate had a higher performance score compared to hospitals with 
a high accrual rate. We observed a learning curve in hospitals with high accrual 
rates, as more errors/violations were observed in the first three included 
patients per trial.  
 
Discussion 
 
Trial performance, evaluated by a composite score including stratification 
errors, major protocol violations, SAE reporting and the inclusion of ineligible 
patients, was comparable between different types of hospitals. We were not 
able to explain the variation in our composite score between hospitals, even 
though we included data from three large clinical trials. This implies that, 
without proper validation, our composite score apparently is insufficient as an 
instrument to evaluate the trial performance of hospitals. However, our finding 
of a learning curve in individual hospitals with a high inclusion rate may suggest 
a possible use for our composite score to evaluate trial performance per 
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individual centre over time. Apparently, the experience with the study protocol 
in practice (i.e. after inclusion of several patients) has a relevant impact on the 
quality of trial performance. This may imply either a more intensive training 
schedule before initiation of a trial, and/or increased support during the 
treatment per protocol of the first included patients.  
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Dikke- darm en endeldarm kanker (colorectaal carcinoom, CRC) is een van de 
meest voorkomende vormen van kanker in de westerse wereld. Ongeveer 50 % 
van de patiënten ontwikkelt in de loop van de ziekte uitzaaiingen. De 
meerderheid van deze patiënten zullen behandeld worden met palliatieve 
systemische therapie. De laatste decennia zijn de opties voor systemische 
behandeling aanzienlijk verbeterd, van 5-FU als de enige beschikbare 
chemotherapie naar de behandeling met andere cytotoxische middelen zoals 
oxaliplatin en irinotecan, en doelgerichte behandelingen zoals antilichamen 
tegen de vasculaire endotheliale groeifactor (VEGF) en de epidermale 
groeifactor receptor (EGFR). Deze nieuwe therapieën en de toename van het 
aantal  chirurgische resecties van metastasen hebben geleid tot een stijging van 
de mediane overleving van 10-11 maanden tot op het ogenblik ongeveer 30 
maanden. 
 
De Dutch Colorectal Cancer Group (DCCG) is een nationale multidisciplinaire 
studiegroep met als doel het stimuleren van klinisch onderzoek en het 
verbeteren van de kwaliteit van de diagnose en behandeling van patiënten met 
colorectaal carcinoom in Nederland. In januari 2003 is de DCCG de CAIRO studie 
gestart, een gerandomiseerde fase 3 studie in patiënten met gemetastaseerd 
colorectaal carcinoom (mCRC). Daarna zijn er 2133 patiënten met mCRC 
behandeld in drie opeenvolgende fase 3 studies. De vierde, vijfde en zesde zijn 
op dit moment open voor inclusie. CAIRO is een acroniem voor de 
geneesmiddelen gebruikt in de eerste studie: Capecitabine, IRinotecan en 
Oxaliplatin. De resultaten van deze 3 studies zijn geïmplementeerd in de 
nationale en internationale richtlijnen. 
 
 
Prospectief monitoren van dodelijke ernstige ongewenste voorvallen 
 
Vroege en correcte beoordeling van overlijdens gerelateerd aan de behandeling 
is belangrijk in oncologisch onderzoek. Om zonder vertraging deze cruciale 
informatie te verzamelen moeten ernstige ongewenste voorvallen (SAE’s) 
binnen 24 uur gemeld worden. De SAE’s worden centraal verzameld, beoordeeld 
door de hoofdonderzoeker(s) en/of studiecoördinator. Daarna worden de SAE’s 
beoordeeld door een onafhankelijke commissie, de Independent Data 
Monitoring Committee (IDMC). Dit systeem om de veiligheid te monitoren is 
sterk afhankelijk van de vroege en betrouwbare beoordeling van SAE’s. In 
hoofdstuk 2 bekijken we de kwaliteit van het rapporteren van SAE’s. De 
studiecoördinatoren hebben op locatie in het ziekenhuis de statussen van alle 
patiënten ingezien die binnen 30 dagen na de laatste toediening van de 
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chemotherapie overleden, behalve als er duidelijk sprake was van progressieve 
ziekte. Alle overlijdens binnen 30 dagen waren gemeld als SAE. De relatie van 
de behandeling met de studiemedicatie werd ingedeeld in niet, gering, 
mogelijk, waarschijnlijk en zeker gerelateerd, en werden daarna ingediend bij 
de IDMC van de studie. Veertig van de 112 patiënten die binnen 30 dagen waren 
overleden voldeden aan de criteria voor beoordeling. De relatie tussen de 
doodsoorzaak en de studiemedicatie zoals in eerste instantie gerapporteerd 
door de lokale onderzoeker werd veranderd in 26 patiënten (65 %). In 12 van de 
14 patiënten met een waarschijnlijke relatie tussen de studiemedicatie en het 
overlijden werd een ernstige protocol afwijking (MPV) gevonden. Naast de 
MPV’s werden ook vier patiënten gevonden die niet voldeden aan de in- en 
exclusiecriteria van de studie. Deze informatie was niet eerder gevonden 
tijdens reguliere verwerking van de gegevens. We concludeerden dat er weinig 
overeenkomst was tussen de lokale onderzoeker en de IDMC in de beoordeling 
van de relatie tussen de studiebehandeling en het overlijden binnen 30 dagen 
na de laatste studiebehandeling, en dat de studiebehandeling als doodsoorzaak 
vaak onderschat wordt. Deze kwaliteitscontrole verbetert de beoordeling van 
de veiligheid van de studiemedicatie. 
 
Een vergelijking van de behandeluitkomsten in een klinische trial versus de 
dagelijkse praktijk 
 
Al is het niet ondersteund door bewijs, er wordt over het algemeen gedacht dat 
de behandeling van patiënten binnen studieverband de uitkomst verbetert, 
bijvoorbeeld doordat deze patiënten meer aandacht krijgen in vergelijking met 
patiënten die buiten een studie behandeld worden. In de CAIRO studie werden 
cytostatica gebruikt in een standaard schema uit de dagelijkse praktijk op 
standaard doseringen, evenals de toelatings-voorwaarden en 
veiligheidscriteria. Dit maakte het mogelijk een vergelijking te maken tussen 
patiënten in een trial en patiënten uit de dagelijkse praktijk.  
Om een tijdige voltooiing van studies mogelijk te maken is het belangrijk om 
zo veel mogelijk patiënten in trials te includeren. Een gebruikelijke behaalde 
participatie is 5-14% binnen alle kankerpatiënten en 30% in meer geselecteerde 
populaties. Met behulp van gegevens uit de Nederlandse Kankerregistratie 
(NKR) was het mogelijk om de deelname van darmkanker patiënten in studies 
tijdens de inclusie periode van de CAIRO studie te bepalen. In hoofdstuk 3 
vergelijken we de uitkomst van de behandeling van patiënten met 
gemetastaseerde darmkanker geïncludeerd in deze trial met patiënten die 
behandeld zijn in de dagelijkse praktijk. Stadium IV darmkanker patiënten 
behandeld in de CAIRO studie werden vergeleken met patiënten in de zelfde 
periode de zelfde behandeling kregen in de dagelijkse praktijk in 29 
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Nederlandse ziekenhuizen. Patiënten behandeld buiten studieverband werden 
uit de NKR gehaald en in de status gecheckt op de in- en exclusiecriteria van 
de CAIRO studie. Tijdens de inclusieperiode werden er 1946 stadium IV 
darmkanker patiënten geregistreerd in de NKR die een behandeling met 
chemotherapie kregen. Hiervan waren er 394 patiënten geïncludeerd in de 
CAIRO studie, 20 %. We zagen geen verschil in overleving tussen patiënten die 
deelnamen aan de studie en patiënten die in aanmerking hadden kunnen komen 
die in de dagelijkse praktijk behandeld werden (HR 1.03, p=0.70). Echter, 
patiënten die tijdens de zelfde periode werden behandeld buiten 
studieverband, die niet aan de in- en exclusiecriteria voldeden hadden een 
significant slechtere uitkomst (HR 1.7, p<0.01). We concluderen dat studie-
resultaten alleen naar de algehele populatie geëxtrapoleerd kunnen worden als 
de zelfde selectiecriteria worden toegepast. We zagen dat 20 % van alle 
patiënten met stadium IV darmkanker die chemotherapie kregen, deelnamen 
aan de CAIRO studie. Als we alle gediagnostiseerde stadium IV patiënten 
meenemen is de deelname aan de studie 10 %. 
 
 
De prognostisch waarde van de WHO performance status en kwaliteit van 
leven in darmkanker patiënten 
 
De performance status (PS) is een bekende prognostisch factor in patiënten met 
kanker en wordt normaal gescoord door de behandeld arts. De EORTC QLQ-C30 
vragenlijst ingevuld door patiënten is een gevalideerde methode om de 
kwaliteit van leven (KvL) te bepalen. Subjectiviteit speelt mee in beide 
methoden, en gegevens over een onderlinge vergelijking zijn er niet veel. In 
hoofdstuk 4 hebben we binnen de CAIRO studie de prognostische waarde van 
de WHO PS vergeleken met de Physical function (PF) schaal van de QLQ-C30. 
Patiënten werden verdeeld in 2 groepen op basis van de uitgangswaarde van de 
Physical function schaal van de EORTC QLQ-C30. KvL werd beschouwd als 
“goed” als de PF score hoger was dan 66.7 %. “Slechte” KvL was gedefinieerd 
als aan PF score van 66.7 % of minder. De prognostische waarde van de WHO PS 
en de PF schaal op de overleving werden met elkaar vergeleken. Deze 
resultaten werden daarna gevalideerd in de CAIRO2 studie.  
De mediane overleving voor patiënten met een ‘goede” QLQ-C30 PF en een 
“slechte” PF in patiënten met WHO PS 0, was 20.3 maanden (n=300) en 10.4 
maanden (n=44), in patiënten met WHO PS 1 16.8 maanden (n=125) en 10.1 
maanden (n=63), en in patiënten met WHO PS 2 16.2 maanden (n=11) en 9.9 
maanden (n=12). In een Cox regressie model waarbij andere prognostische 
factoren werden toegevoegd was “goede” versus “slechte”QLQ-C30 PF een 
significante prognostische factor voor overleving (HR 0.57 95% CI 0.46-0.72),  
WHO PS niet. Deze resultaten werden bevestigd in de CAIRO2 studie. We 
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concludeerden dat door patiënten gerapporteerde QLQ-C30 PF beter 
voorspellend was dan de door de arts gerapporteerde WHO PS. 
 
De kwaliteit van klinische trials in gemetastaseerde darmkanker 
 
De kwaliteit van gegevens uit klinisch onderzoek is afhankelijk van veel 
verschillende factoren. Onder andere het gebruik van adequate methodologie 
en protocollen om betrouwbare en valide resultaten te verkrijgen. Ondanks dat 
er geen valide indicatoren voor de uitvoer van klinisch onderzoek zijn, zou het 
aantal afwijkingen van het studieprotocol mogelijk een toepasbare indicator 
zijn voor de naleving van het protocol. Gegevens over de naleving van studie 
protocollen zijn echter schaars. Ernstige afwijkingen van het protocol  zijn 
gedefinieerd als afwijkingen die zouden kunnen  leiden tot schade bij de patiënt 
of die een impact zouden kunnen hebben op de integriteit van de gegevens. 
Het aantal geïncludeerde studie patiënten per deelnemend ziekenhuis is eerder 
voorgesteld als een mogelijke indicator voor de kwaliteit van klinisch 
onderzoek.  Er zijn tegenstrijdige resultaten over de invloed van het type 
ziekenhuis op de kwaliteit van klinisch onderzoek. In hoofdstuk 5 rapporteren 
we de evaluatie van de kwaliteit van klinisch onderzoek door middel van een 
samengestelde score in drie grote fase 3 studies met systemische behandeling 
in darmkanker patiënten in Nederland. Deze score bestond uit 
stratificatiefouten, ernstige afwijkingen van het protocol, SAE rapportage en 
de inclusie van patiënten die niet aan de in- en exclusiecriteria voldeden. 
Hiernaast hebben we een vragenlijst verstuurd naar de ziekenhuizen waarin 
onder andere werd gevraagd naar het aantal bedden, medisch oncologen en 
researchverpleegkundigen. Ziekenhuizen werden verdeeld in 3 categorieën: 
universitaire, opleidings- en regionale ziekenhuizen. De inclusie was hoger in 
de universitaire en opleidings- ziekenhuizen vergeleken met de regionale 
ziekenhuizen. Een grote variatie werd gezien in de uitvoer van een studie tussen 
ziekenhuizen, maar individuele factoren zoals het aantal bedden, het aantal 
medisch oncologen of de aanwezigheid van een researchverpleegkundige 
konden deze variatie niet verklaren. Er werd geen verschil in de kwaliteit van 
klinisch onderzoek gezien tussen de drie typen ziekenhuizen. Ziekenhuizen met 
een lage inclusie hadden een hogere score vergeleken met ziekenhuizen met 
een hoge inclusie. We zagen een leercurve in ziekenhuizen met een hoge 
inclusie, in de eerste drie geïncludeerde patiënten werden meer fouten gezien 
dan daarna.  
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